Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 100 of 1567 matching drugs for PTPRD — including drugs targeting any of its 22 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
docetaxel, thalidomide BCL2 SSL via BCL2 4
docetaxel, thalidomide MAP2 SSL via MAP2 4
docetaxel, thalidomide MAP4 SSL via MAP4 4
docetaxel, thalidomide MAPT SSL via MAPT 4
docetaxel, thalidomide NR1I2 SSL via NR1I2 4
docetaxel, thalidomide TUBB1 SSL via TUBB1 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab BCL2 SSL via BCL2 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab MAP2 SSL via MAP2 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab MAP4 SSL via MAP4 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab MAPT SSL via MAPT 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab NR1I2 SSL via NR1I2 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab TUBB1 SSL via TUBB1 4
amg 193, docetaxel, comparator amg 193 test tablet BCL2 SSL via BCL2 3
amg 193, docetaxel, comparator amg 193 test tablet MAP2 SSL via MAP2 3
amg 193, docetaxel, comparator amg 193 test tablet MAP4 SSL via MAP4 3
amg 193, docetaxel, comparator amg 193 test tablet MAPT SSL via MAPT 3
amg 193, docetaxel, comparator amg 193 test tablet NR1I2 SSL via NR1I2 3
amg 193, docetaxel, comparator amg 193 test tablet TUBB1 SSL via TUBB1 3
bms-986340, bms-936558-01, docetaxel BCL2 SSL via BCL2 3
bms-986340, bms-936558-01, docetaxel MAP2 SSL via MAP2 3
bms-986340, bms-936558-01, docetaxel MAP4 SSL via MAP4 3
bms-986340, bms-936558-01, docetaxel MAPT SSL via MAPT 3
bms-986340, bms-936558-01, docetaxel NR1I2 SSL via NR1I2 3
bms-986340, bms-936558-01, docetaxel TUBB1 SSL via TUBB1 3
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel BCL2 SSL via BCL2 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel MAP2 SSL via MAP2 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel MAP4 SSL via MAP4 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel MAPT SSL via MAPT 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel NR1I2 SSL via NR1I2 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel TUBB1 SSL via TUBB1 2
alvocidib, paclitaxel BCL2 SSL via BCL2 2
alvocidib, paclitaxel MAP2 SSL via MAP2 2
alvocidib, paclitaxel MAP4 SSL via MAP4 2
alvocidib, paclitaxel MAPT SSL via MAPT 2
alvocidib, paclitaxel NR1I2 SSL via NR1I2 2
alvocidib, paclitaxel TUBB1 SSL via TUBB1 2
asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan BCL2 SSL via BCL2 2
asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan MAP2 SSL via MAP2 2
asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan MAP4 SSL via MAP4 2
asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan MAPT SSL via MAPT 2
asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan NR1I2 SSL via NR1I2 2
asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan TUBB1 SSL via TUBB1 2
bbi-355, erlotinib, futibatinib NR1I2 SSL via NR1I2 2
biopsy, biospecimen collection, computed tomography, cyclophosphamide, fludarabine phosphate, fludeoxyglucose f-18, il13ralpha2-specific hinge-optimized 4-1bb-co-stimulatory car/truncated cd19-expressing autologous tn/mem cells, magnetic resonance imaging, positron emission tomography NR1I2 SSL via NR1I2 2
bpi-7711, bpi-7711, itraconazole, rifampicin NR1I2 SSL via NR1I2 2
bryostatin 1, paclitaxel BCL2 SSL via BCL2 2
bryostatin 1, paclitaxel MAP2 SSL via MAP2 2
bryostatin 1, paclitaxel MAP4 SSL via MAP4 2
bryostatin 1, paclitaxel MAPT SSL via MAPT 2
bryostatin 1, paclitaxel NR1I2 SSL via NR1I2 2
bryostatin 1, paclitaxel TUBB1 SSL via TUBB1 2
btla inhibitor (js004), toripalimab, paclitaxel, cisplatin BCL2 SSL via BCL2 2
btla inhibitor (js004), toripalimab, paclitaxel, cisplatin MAP2 SSL via MAP2 2
btla inhibitor (js004), toripalimab, paclitaxel, cisplatin MAP4 SSL via MAP4 2
btla inhibitor (js004), toripalimab, paclitaxel, cisplatin MAPT SSL via MAPT 2
btla inhibitor (js004), toripalimab, paclitaxel, cisplatin NR1I2 SSL via NR1I2 2
btla inhibitor (js004), toripalimab, paclitaxel, cisplatin TUBB1 SSL via TUBB1 2
cabazitaxel TUBB1 SSL via TUBB1 2
capecitabine, docetaxel BCL2 SSL via BCL2 2
capecitabine, docetaxel MAP2 SSL via MAP2 2
capecitabine, docetaxel MAP4 SSL via MAP4 2
capecitabine, docetaxel MAPT SSL via MAPT 2
capecitabine, docetaxel NR1I2 SSL via NR1I2 2
capecitabine, docetaxel TUBB1 SSL via TUBB1 2
carboplatin, celecoxib, paclitaxel, adjuvant therapy, conventional surgery, neoadjuvant therapy BCL2 SSL via BCL2 2
carboplatin, celecoxib, paclitaxel, adjuvant therapy, conventional surgery, neoadjuvant therapy MAP2 SSL via MAP2 2
carboplatin, celecoxib, paclitaxel, adjuvant therapy, conventional surgery, neoadjuvant therapy MAP4 SSL via MAP4 2
carboplatin, celecoxib, paclitaxel, adjuvant therapy, conventional surgery, neoadjuvant therapy MAPT SSL via MAPT 2
carboplatin, celecoxib, paclitaxel, adjuvant therapy, conventional surgery, neoadjuvant therapy NR1I2 SSL via NR1I2 2
carboplatin, celecoxib, paclitaxel, adjuvant therapy, conventional surgery, neoadjuvant therapy TUBB1 SSL via TUBB1 2
carboplatin, docetaxel BCL2 SSL via BCL2 2
carboplatin, docetaxel MAP2 SSL via MAP2 2
carboplatin, docetaxel MAP4 SSL via MAP4 2
carboplatin, docetaxel MAPT SSL via MAPT 2
carboplatin, docetaxel NR1I2 SSL via NR1I2 2
carboplatin, docetaxel TUBB1 SSL via TUBB1 2
carboplatin, endoscopic biopsy, external beam radiation therapy, lenvatinib mesylate, paclitaxel, pembrolizumab, resection BCL2 SSL via BCL2 2
carboplatin, endoscopic biopsy, external beam radiation therapy, lenvatinib mesylate, paclitaxel, pembrolizumab, resection MAP2 SSL via MAP2 2
carboplatin, endoscopic biopsy, external beam radiation therapy, lenvatinib mesylate, paclitaxel, pembrolizumab, resection MAP4 SSL via MAP4 2
carboplatin, endoscopic biopsy, external beam radiation therapy, lenvatinib mesylate, paclitaxel, pembrolizumab, resection MAPT SSL via MAPT 2
carboplatin, endoscopic biopsy, external beam radiation therapy, lenvatinib mesylate, paclitaxel, pembrolizumab, resection NR1I2 SSL via NR1I2 2
carboplatin, endoscopic biopsy, external beam radiation therapy, lenvatinib mesylate, paclitaxel, pembrolizumab, resection TUBB1 SSL via TUBB1 2
carboplatin, esophagectomy, intensity-modulated radiation therapy, paclitaxel, proton beam radiation therapy, quality-of-life assessment, questionnaire administration, folfox regimen, capox regimen, docetaxel, 5fu BCL2 SSL via BCL2 2
carboplatin, esophagectomy, intensity-modulated radiation therapy, paclitaxel, proton beam radiation therapy, quality-of-life assessment, questionnaire administration, folfox regimen, capox regimen, docetaxel, 5fu MAP2 SSL via MAP2 2
carboplatin, esophagectomy, intensity-modulated radiation therapy, paclitaxel, proton beam radiation therapy, quality-of-life assessment, questionnaire administration, folfox regimen, capox regimen, docetaxel, 5fu MAP4 SSL via MAP4 2
carboplatin, esophagectomy, intensity-modulated radiation therapy, paclitaxel, proton beam radiation therapy, quality-of-life assessment, questionnaire administration, folfox regimen, capox regimen, docetaxel, 5fu MAPT SSL via MAPT 2
carboplatin, esophagectomy, intensity-modulated radiation therapy, paclitaxel, proton beam radiation therapy, quality-of-life assessment, questionnaire administration, folfox regimen, capox regimen, docetaxel, 5fu NR1I2 SSL via NR1I2 2
carboplatin, esophagectomy, intensity-modulated radiation therapy, paclitaxel, proton beam radiation therapy, quality-of-life assessment, questionnaire administration, folfox regimen, capox regimen, docetaxel, 5fu TUBB1 SSL via TUBB1 2
carboplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy BCL2 SSL via BCL2 2
carboplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy MAP2 SSL via MAP2 2
carboplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy MAP4 SSL via MAP4 2
carboplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy MAPT SSL via MAPT 2
carboplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy NR1I2 SSL via NR1I2 2
carboplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy TUBB1 SSL via TUBB1 2
carboplatin, paclitaxel, panitumumab, radiotherapy BCL2 SSL via BCL2 2
carboplatin, paclitaxel, panitumumab, radiotherapy MAP2 SSL via MAP2 2
carboplatin, paclitaxel, panitumumab, radiotherapy MAP4 SSL via MAP4 2
carboplatin, paclitaxel, panitumumab, radiotherapy MAPT SSL via MAPT 2
carboplatin, paclitaxel, panitumumab, radiotherapy NR1I2 SSL via NR1I2 2
carboplatin, paclitaxel, panitumumab, radiotherapy TUBB1 SSL via TUBB1 2
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.